Top Ten most popular articles on Pharmafile.com this week
pharmafile | September 13, 2019 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |
It’s Friday again and time for another rundown of the top most popular articles on Pharmafile.com this week. This past week saw Novo Nordisk launch a huge price cut for its insulin drug Novolog as well as good and bad news for Bristol Myers Squibb’s Opdivo.
10. Vertex cystic fibrosis drugs become available in Scotland after NHS rejection
Two potentially life-changing cystic fibrosis drugs are to become available for a potential pool of 400 patients in Scotland just a month after they were rejected by the NHS.
Though MPs are moving forward with their plan to block UK Prime Minister Boris Johnson’s supposed no-deal Brexit from the EU and the economic and medical harm that would cause, it has become known that Ireland will not succumb to the same medicine access issues that threaten too affect England.
8. Boehringer’s Ofev scores first-of-its-kind FDA approval in rare lung disease
Boehringer Ingelheim’s Ofev (nintedanib) capsules have now secured marketing authorisation in the US, it has emerged, for the treatment of interstitial lung disease associated with systemic sclerosis or scleroderma (SSc-ILD), a rare lung condition.
7. BMS unveils strong five-year efficacy data for Opdivo in lung cancer
Bristol-Myers Squibb has unveiled pooled five-year efficacy and safety results for its blockbuster immunotherapy Opdivo (nivolumab) drawn from two Phase 3 studies in the treatment of previously treated advanced non-small cell lung cancer (NSCLC).
6. BMS’ Opdivo falls short at Phase 3 in glioblastoma multiforme
Bristol-Myers Squibb has revealed that its blockbuster immunotherapy Opdivo (nivolumab) fell short of its primary Phase 3 endpoint in the treatment of newly diagnosed glioblastoma multiforme (GBM) when combined with the current standard of care, temozolomide and radiation therapy).
5. Decade-long data support Biogen’s Tecfidera in relapsing multiple sclerosis
Biogen has revealed new long-term data for Tecfidera (dimethyl fumarate), reinforcing the benefits of the therapy over a decade-long period in the treatment of relapsing multiple sclerosis (MS).
4. Roche’s satralizumab succeeds in second positive study in rare CNS disease
In a second pivotal Phase 3 study of Roche’s satralizumab, the drug showed itself to significantly reduce relapse risk for neuromyelitis optica spectrum disorder (NMOSD), a rare central nervous system disease.
3. Decade-long data support Biogen’s Tecfidera in relapsing multiple sclerosis
Biogen has revealed new long-term data for Tecfidera (dimethyl fumarate), reinforcing the benefits of the therapy over a decade-long period in the treatment of relapsing multiple sclerosis (MS).
2. GlaxoSmithKline acquires Sitari Pharmaceuticals after progress in coeliac disease
Avalon Ventures has announced that it has entered into a definitive agreement with GSK for the acquisition of Sitari Pharmaceuticals for its novel treatment for coeliac disease.
Danish drug maker Novo Nordisk has said it will offer a generic version of NovoLog (insulin aspart) at a price of $145 per vial, nearly half of the branded drug’s currently listed price. The price cut will come into effect from January 2020.
